Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dustin McCurry

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|July 3, 2023
Immune-based therapies in diffuse large B-cell lymphomaDustin McCurry, Christopher R Flowers, Casey Bermack
Leukemia & Lymphoma|March 9, 2023
CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacyAjlan Al Zaki, Dustin McCurry, Paolo Strati
Ticks and Tick-Borne Diseases|July 30, 2020
Severe anaplasmosis represents a treatable cause of secondary hemophagocytic lymphohistiocytosis: Two cases and review of literatureJoseph M Rocco, Christina Mallarino-Haeger, Dustin McCurry, et al.
Cancer Research|November 4, 2010
A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironmentAngela D Pardee, Dustin McCurry, Sean Alber, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
<i>ASXL1</i> truncating mutations drive leukemic resistance to T cell attackDustin McCurry, Zhongqi Ge, Jaehyun Lee, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromesYu-Hsiang Chen, Timothy Bi, Minhang Xu, et al.
Nature Cancer|January 9, 2025
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinomaTejas Jammihal, Renee Maria Saliby, Chris Labaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G Najjar, Dustin McCurry, Huang Lin, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|July 3, 2023
Immune-based therapies in diffuse large B-cell lymphomaDustin McCurry, Christopher R Flowers, Casey Bermack
Leukemia & Lymphoma|March 9, 2023
CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacyAjlan Al Zaki, Dustin McCurry, Paolo Strati
Ticks and Tick-Borne Diseases|July 30, 2020
Severe anaplasmosis represents a treatable cause of secondary hemophagocytic lymphohistiocytosis: Two cases and review of literatureJoseph M Rocco, Christina Mallarino-Haeger, Dustin McCurry, et al.
Cancer Research|November 4, 2010
A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironmentAngela D Pardee, Dustin McCurry, Sean Alber, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
<i>ASXL1</i> truncating mutations drive leukemic resistance to T cell attackDustin McCurry, Zhongqi Ge, Jaehyun Lee, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromesYu-Hsiang Chen, Timothy Bi, Minhang Xu, et al.
Nature Cancer|January 9, 2025
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinomaTejas Jammihal, Renee Maria Saliby, Chris Labaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G Najjar, Dustin McCurry, Huang Lin, et al.
Pageof 1